Long-term outcome with the use of OKT3 induction therapy in heart transplant patients: a single-center experience.
Adamson
R
R
Sharp Memorial Heart Transplant Center, San Diego, California, USA.
Obispo
E
E
Dychter
S
S
Dembitsky
W
W
Moreno-Cabral
R
R
Jaski
B
B
Gordon
J
J
Hoagland
P
P
Moore
K
K
King
J
J
Andrews
J
J
Rich
M
M
Daily
P O
PO
D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D016027:Heart Transplantation / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009369:Neoplasms / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids; D016572:Cyclosporine; D001379:Azathioprine